Our Science – Flanders Website
Kathleen C. Flanders, Ph.D.
Dr. Flanders developed some of the first isoform-specific antibodies to TGF-beta to be widely used in immunohistochemistry. She has extensive experience in analysis of components of the TGF-beta signaling pathway in tissues relating to many in vivo models of wound healing and disease pathogenesis. She has studied the role of TGF-beta and its signaling intermediate, Smad3, in chornic fibrotic conditions such as radiation-induced fibrosis showing that loss of Smad3 inhibits fibrosis. These results suggest that development of small molecule inhibitors of Smad3 may be useful as potential anti-fibrotic therapeutic agents. She is currently interested in the tumor microenvironment and is investigating the potential involvement of TGF-beta in mediating the condition of high mammographic density (HMD)which is a significant risk factor for breast cancer. Development of a mouse model of HMD as well as analysis of TGF-beta pathway components in human HMD samples are currently underway. The signaling pathways activated by TGF-beta isoforms in human mammary fibroblasts in vitro are also being analyzed.
This page was last updated on 2/26/2013.